Analyst David Martin PhD of Bloom Burton maintained a Buy rating on Medicenna Therapeutics Corp, retaining the price target of $6.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
David Martin PhD’s rating is based on the growing interest in PD-1 bispecific antibodies within the pharmaceutical industry, as evidenced by recent high-value deals. Medicenna Therapeutics Corp is well-positioned in this promising field, which has seen significant investments from major players like Merck, Pfizer, and Takeda.
The strategic partnerships and substantial upfront payments in the sector highlight the potential value and demand for innovative oncology treatments. This context suggests that Medicenna’s focus on PD-1/IL-2 bispecifics could lead to lucrative opportunities, justifying the Buy rating.
Martin PhD covers the Healthcare sector, focusing on stocks such as Aurinia Pharmaceuticals, Medicenna Therapeutics Corp, and HLS Therapeutics Inc. According to TipRanks, Martin PhD has an average return of 17.3% and a 48.44% success rate on recommended stocks.
In another report released on October 14, Lucid Capital also initiated coverage with a Buy rating on the stock with a C$4.00 price target.